Tivic is a late-stage immunotherapeutics company whose lead drug candidate, Entolimod™ to treat Acute Radiation Syndrome (ARS), is in late-stage development. Entolimod™ is a TLR5 agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age.

The pipeline also includes Entolimod™ to treat Neutropenia, and lymphocyte exhaustion, as well as Entolasta™, an immunologically optimized variant of Entolimod for chronic applications.

Please visit Tivic’s pipeline page to learn more about the company’s drug development plans, including the complete list of drugs under development.

Tivic also has a wholly owned subsidiary, Velocity Bioworks, which is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. Tivic also leverages Velocity Bioworks’ manufacturing capabilities to advance its own drug pipeline with the expected benefits of lower costs, accelerated manufacturing outcomes and supply chain security.